In this article, we will discuss Emapalumab-lzsg (Dosage Overview). So, let’s get started.
Emapalumab-lzsg is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
The recommended starting dose of Emapalumab-lzsg is 1 mg/kg given as an intravenous infusion over 1 hour twice per week (every three to four days). Doses subsequent to the initial dose may be increased based on clinical and laboratory criteria.
Administer Emapalumab-lzsg until hematopoietic stem cell transplantation (HSCT) is performed or unacceptable toxicity. Discontinue Emapalumab-lzsg when a patient no longer requires therapy for the treatment of HLH.